

1A-587-T100

Monoclonal Antibody to CD135 Allophycocyanin (APC) conjugated (100 tests)

Clone: BV10A4

Isotype: Mouse IqG1

Specificity: The mouse monoclonal antibody BV10A4 (BV10) reacts with CD135 (FLT3, FLK2,

STK-1), a 130-160 kDa type I transmembrane receptor tyrosine kinase that is

involved in early steps of hematopoiesis.

Regulatory Status: RUO

Immunogen: BV-173 leukemic cell line

Species Reactivity: Human **Negative Species:** Mouse

Preparation: The purified antibody is conjugated with cross-linked Allophycocyanin (APC) under

optimum conditions. The conjugate is purified by size-exclusion chromatography

and adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μ l reagent / 100 μ l of whole blood or 10 6 cells in a suspension. Usage:

The content of a vial (1 ml) is sufficient for 100 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135

homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on

various malignant hematopoietic cells.



PRODUCT DATA SHEET

References:

*Rappold I, Ziegler BL, Köhler I, Marchetto S, Rosnet O, Birnbaum D, Simmons PJ, Zannettino AC, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L, Bühring HJ: Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 1997 Jul 1;90(1):111-25.

*Christensen JL, Weissman IL: Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14541-6.

*Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16741-6.

*Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica. 2005 Dec;90(12):1617-25.

*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). *Haylock DN, Horsfall MJ, Dowse TL, Ramshaw HS, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring HJ, Simmons PJ: Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood. 1997 Sep 15;90(6):2260-72.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.